Targeted immunomodulation using antigen-conjugated nanoparticles
ABSTRACT The growing prevalence of nanotechnology in the fields of biology, medicine, and the pharmaceutical industry is confounded by the relatively small amount of data on the impact of these materials on the immune system. In addition to concerns surrounding the potential toxicity of nanoparticle...
Saved in:
Published in: | Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Vol. 6; no. 3; pp. 298 - 315 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Hoboken, USA
John Wiley & Sons, Inc
01-05-2014
Wiley Subscription Services, Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | ABSTRACT
The growing prevalence of nanotechnology in the fields of biology, medicine, and the pharmaceutical industry is confounded by the relatively small amount of data on the impact of these materials on the immune system. In addition to concerns surrounding the potential toxicity of nanoparticle (NP)‐based delivery systems, there is also a demand for a better understanding of the mechanisms governing interactions of NPs with the immune system. Nanoparticles can be tailored to suppress, enhance, or subvert recognition by the immune system. This ‘targeted immunomodulation’ can be achieved by delivery of unmodified particles, or by modifying particles to deliver drugs, proteins/peptides, or genes to a specific site. In order to elicit the desired, beneficial immune response, considerations should be made at every step of the design process: the NP platform itself, ligands, and other modifiers, the delivery route, and the immune cells that will encounter the conjugated NPs can all impact host immune responses.
This article is categorized under:
Therapeutic Approaches and Drug Discovery > Emerging Technologies
Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease |
---|---|
Bibliography: | istex:66C4B20CCDF4FBF8BCDB3C5DC68E92AD892B331E Myelin Repair Foundation National Multiple Sclerosis Society ark:/67375/WNG-29Q4K71F-V ArticleID:WNAN1263 Juvenile Diabetes Research Foundation National Institutes of Health Conflict of interest: The authors have declared no conflicts of interest for this article. Authors contributed equally |
ISSN: | 1939-5116 1939-0041 |
DOI: | 10.1002/wnan.1263 |